- Home
- AVPT vs ZLAB Comparison
AVPT vs ZLAB Comparison
Compare AVPT & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVPT
- ZLAB
- Stock Information
- Founded
- AVPT 2001
- ZLAB 2013
- Country
- AVPT United States
- ZLAB China
- Employees
- AVPT N/A
- ZLAB N/A
- Industry
- AVPT Computer Software: Prepackaged Software
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- AVPT Technology
- ZLAB Health Care
- Exchange
- AVPT Nasdaq
- ZLAB Nasdaq
- Market Cap
- AVPT 3.8B
- ZLAB 3.6B
- IPO Year
- AVPT N/A
- ZLAB 2017
- Fundamental
- Price
- AVPT $15.17
- ZLAB $32.94
- Analyst Decision
- AVPT Buy
- ZLAB Buy
- Analyst Count
- AVPT 5
- ZLAB 6
- Target Price
- AVPT $19.80
- ZLAB $57.22
- AVG Volume (30 Days)
- AVPT 1.3M
- ZLAB 647.2K
- Earning Date
- AVPT 11-06-2025
- ZLAB 11-11-2025
- Dividend Yield
- AVPT N/A
- ZLAB N/A
- EPS Growth
- AVPT N/A
- ZLAB N/A
- EPS
- AVPT N/A
- ZLAB N/A
- Revenue
- AVPT $373,069,000.00
- ZLAB $427,799,000.00
- Revenue This Year
- AVPT $26.18
- ZLAB $41.60
- Revenue Next Year
- AVPT $18.16
- ZLAB $53.42
- P/E Ratio
- AVPT N/A
- ZLAB N/A
- Revenue Growth
- AVPT 24.41
- ZLAB 32.56
- 52 Week Low
- AVPT $11.61
- ZLAB $23.70
- 52 Week High
- AVPT $20.25
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- AVPT 45.55
- ZLAB 49.48
- Support Level
- AVPT $14.80
- ZLAB $32.87
- Resistance Level
- AVPT $15.26
- ZLAB $33.97
- Average True Range (ATR)
- AVPT 0.38
- ZLAB 0.91
- MACD
- AVPT 0.02
- ZLAB 0.13
- Stochastic Oscillator
- AVPT 42.00
- ZLAB 51.61
About AVPT AvePoint Inc.
AvePoint Inc provides customizable solutions to optimize SaaS operations, enable secure collaboration, and accelerate digital transformation across technologies and industries. Its Confidence Platform delivers a comprehensive set of cloud-based solutions enabling IT operations, development operations, and cybersecurity professionals to monitor and secure the digital workplace using SaaS tools.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.